4-(甲基磺酰氧甲基)-1,2-O-二乙酰氧基-3,5-O-二苄基-alpha-D-赤式戊呋喃糖 | 221229-65-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-(甲基磺酰氧甲基)-1,2-O-二乙酰氧基-3,5-O-二苄基-alpha-D-赤式戊呋喃糖
• 中文别名: 4-(甲基磺酰氧甲基)-1,2-O-二乙酰氧基-3,5-O-二苄基-ALPHA-D-赤式戊呋喃糖
• 英文名称: 1,2-di-O-acetyl-3-O-benzyl-4-C-[(benzyloxy)methyl]-5-O-(methylsulfonyl)-L-lyxofuranose
• 英文别名: 1,2-di-O-acetyl-3-O-benzyl-4-[(benzyloxy)methyl]-5-O-methylsulfonyl-L-lyxofuranose；1,2-Di-O-acetyl-3-O-benzyl-4-C-(phenylmethoxy)methyl-L-Lyxofuranose 5-methanesulfonate；[(3R,4S,5S)-2-acetyloxy-5-(methylsulfonyloxymethyl)-4-phenylmethoxy-5-(phenylmethoxymethyl)oxolan-3-yl] acetate
• CAS: 221229-65-8
• 化学式: C₂₅H₃₀O₁₀S
• 分子量: 522.573
• InChiKey: DZNOYTCPAYPNAK-JJZURMAISA-N

物化性质

• 密度：
  1.32

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  36
• 可旋转键数：
  14
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  132
• 氢给体数：
  0
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  4-(甲基磺酰氧甲基)-1,2-O-二乙酰氧基-3,5-O-二苄基-alpha-D-赤式戊呋喃糖 在 吡啶 、 N,O-双三甲硅基乙酰胺 、 lithium hydroxide monohydrate 作用下， 以 四氢呋喃 、 水 、 1,2-二氯乙烷 为溶剂， 反应 22.0h， 生成
  参考文献：
  名称：

  [EN] CYCLIC DINUCLEOTIDES AS STING AGONISTS
  [FR] DINUCLÉOTIDES CYCLIQUES UTILISÉS EN TANT QU'AGONISTES DE STING

  摘要：

  揭示了一种通过调节STING来治疗受影响的疾病、综合征或紊乱的化合物、组合物和方法。这些化合物由以下式（I）表示：其中B2、X2、R2a、R2b、R2c、Z-M-Y、Y1-M1Z1、B1、X1、R1a、R1b、R1c如本文所定义。

  公开号：

  WO2019118839A1
• 作为产物：
  描述：

  1,2-O-(异丙亚基)-4-C-[(苯基甲氧基)甲基]-3-O-(苯基甲基)-beta-L-来苏呋喃糖 在 吡啶 、 水 、 溶剂黄146 作用下， 反应 15.0h， 生成 4-(甲基磺酰氧甲基)-1,2-O-二乙酰氧基-3,5-O-二苄基-alpha-D-赤式戊呋喃糖
  参考文献：
  名称：

  含有新型 4'-C- 或 3'-C-(氨基烷基)-支化胸苷的寡核苷酸

  摘要：

  报道了四种新型 3'-C-支链和 4'-C-支链核苷的合成及其转化为相应的 3'-O-亚磷酰胺结构单元以用于自动寡核苷酸合成。4'-C-支化关键中间体11通过收敛策略合成并转化为其2'-O-甲基和2'-脱氧-2'-氟衍生物，从而制备出含有4'-的新型寡核苷酸类似物C-(氨基甲基)-2'-O-甲基单体X和4'-C-(氨基甲基)-2'-脱氧-2'-氟单体Y(方案2和3)。一般来说，与未修饰的参考相比，这些类似物对互补单链 DNA 和 RNA 的结合亲和力增加（表 1）。2'-O-甲基-RNA寡核苷酸中单体X或单体Y的存在对2'-O-甲基-RNA寡核苷酸对DNA和RNA的结合亲和力具有负面影响。从 3'-C-烯丙基衍生物 28 开始，合成了 3'-C-(3-氨基丙基)-保护的核苷和 3'-O-亚磷酰胺衍生物，从而产生了含有 3'-C-(3-氨基丙基）胸苷单体Z或相应的3'-C-（3-氨基丙基）-2'-O

  DOI：

  10.1002/(sici)1522-2675(20000119)83:1<128::aid-hlca128>3.0.co;2-q

文献信息

• CROSSLINKED NUCLEIC ACID GUNA, METHOD FOR PRODUCING SAME, AND INTERMEDIATE COMPOUND
  申请人：MITSUBISHI TANABE PHARMA CORPORATION

  公开号：US20180251488A1

  公开（公告）日：2018-09-06

  The present invention provides a method for producing guanidine crosslinked artificial nucleic acid (abbreviated hereinafter as GuNA), and an intermediate compound for the production thereof. Specifically, the present invention provides a method for producing a compound represented by general formula I: (in the formula, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , m and ring A are as defined in the specification) or a salt thereof wherein a reducing agent is reacted with a compound represented by general formula II: (in the formula, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , m, and ring A′ are as defined in the specification).

  本发明提供了一种生产胍交联人工核酸（以下简称为GuNA）的方法，以及用于其生产的中间化合物。具体而言，本发明提供了一种生产由通式I表示的化合物的方法：（在该式中，R1、R2、R3、R4、R5、R6、m和环A如规范中定义）或其盐，其中还包括将还原剂与通式II表示的化合物发生反应的步骤：（在该式中，R1、R2、R3、R4、R5、R6、m和环A'如规范中定义）。
• Oligonucleotide analogues
  申请人：Wengel Jesper

  公开号：US20050287566A1

  公开（公告）日：2005-12-29

  The present invention relates to novel bicyclic and tricyclic nucleoside and nucleotide analogues as well as to oligonucleotides comprising such elements. The nucleotide analogues, LNAs (Locked Nucleoside Analogues), are able to provide valuable improvements to oligonucleotides with respect to affinity and specificity towards complementary RNA and DNA oligomers. The novel type of LNA modified oligonucleotides, as well as the LNAs as such, are useful in a wide range of diagnostic applications as well as therapeutic applications. Among these can be mentioned antisense applications, PCR applications, strand displacement oligomers, as substrates for nucleic acid polymerases, as nucleotide based drugs, etc. The present invention also relates to such applications.

  本发明涉及新型的双环和三环核苷酸和核苷酸类似物，以及包含这些元素的寡核苷酸。这些核苷酸类似物，即锁定核苷酸类似物（LNAs），能够为寡核苷酸提供与互补RNA和DNA寡聚物的亲和力和特异性方面的有价值的改进。这种新型的LNA修饰的寡核苷酸以及LNA本身在广泛的诊断应用和治疗应用中非常有用。其中包括反义应用、PCR应用、链置换寡聚物、作为核酸聚合酶的底物、作为基于核苷酸的药物等。本发明还涉及这些应用。
• OLIGONUCLEOTIDE ANALOGUES
  申请人：Wengel Jesper

  公开号：US20100279895A1

  公开（公告）日：2010-11-04

  The present invention relates to novel bicyclic and tricyclic nucleoside and nucleotide analogues as well as to oligonucleotides comprising such elements. The nucleotide analogues, LNAs (Locked Nucleoside Analogues), are able to provide valuable improvements to oligonucleotides with respect to affinity and specificity towards complementary RNA and DNA oligomers. The novel type of LNA modified oligonucleotides, as well as the LNAs as such, are useful in a wide range of diagnostic applications as well as therapeutic applications. Among these can be mentioned antisense applications, PCR applications, strand displacement oligomers, as substrates for nucleic acid polymerases, as nucleotide based drugs, etc. The present invention also relates to such applications.

  本发明涉及新型的双环和三环核苷酸和核苷酸类似物，以及包含这些元素的寡核苷酸。这些核苷酸类似物，即LNAs（锁定核苷酸类似物），能够为寡核苷酸提供与互补RNA和DNA寡聚物相比亲和力和特异性的有价值的改进。这种新型的LNA修饰的寡核苷酸以及LNAs本身在广泛的诊断应用和治疗应用中都有用途。其中可以提到反义应用、PCR应用、链位移寡聚物、作为核酸聚合酶底物、作为核苷酸基药物等。本发明还涉及这些应用。
• Oligonucleotide Analogues
  申请人：WENGEL Jesper

  公开号：US20110245327A1

  公开（公告）日：2011-10-06

  The present invention relates to novel bicyclic and tricyclic nucleoside and nucleotide analogues as well as to oligonucleotides comprising such elements. The nucleotide analogues, LNAs ( L ocked N ucleoside A nalogues), are able to provide valuable improvements to oligonucleotides with respect to affinity and specificity towards complementary RNA and DNA oligomers. The novel type of LNA modified oligonucleotides, as well as the LNAs as such, are useful in a wide range of diagnostic applications as well as therapeutic applications. Among these can be mentioned antisense applications, PCR applications, strand displacement oligomers, as substrates for nucleic acid polymerases, as nucleotide based drugs, etc. The present invention also relates to such applications.

  本发明涉及新型的双环和三环核苷酸和核苷酸类似物，以及包含这些元素的寡核苷酸。核苷酸类似物，即锁定核苷酸类似物（LNAs），能够为寡核苷酸提供有价值的改进，使其对互补的RNA和DNA寡聚体具有更高的亲和力和特异性。这种新型的LNA修饰的寡核苷酸以及LNAs本身在广泛的诊断应用和治疗应用中都很有用。其中包括反义应用、PCR应用、链置换寡聚体、作为核酸聚合酶的底物、作为基于核苷酸的药物等。本发明还涉及这些应用。
• Bi-cyclic nucleoside, nucleotide and oligonucleoide analogues
  申请人：Exiqon A/S

  公开号：EP1557424A1

  公开（公告）日：2005-07-27

  The present invention relates to novel bicyclic and tricyclic nucleoside analogues as well as to oligonucleotides comprising such elements. The nucleotide analogues, LNAs (Locked Nucleoside Analogues), are able to provide valuable improvements to oligonucleotides with respect to affinity and specificity towards complementary RNA and DNA oligomers. The novel type of LNA modified oligonucleotides, as well as the LNAs as such, are useful in a wide range of diagnostic applications as well as therapeutic applications. Among these can be mentioned antisense applications, PCR applications, strand displacement oligomers, as substrates for nucleic acid polymerises, as nucleotide based drugs, etc. The present invention also relates to such applications.

  本发明涉及新型双环和三环核苷类似物以及包含此类元素的寡核苷酸。这种核苷酸类似物 LNA（锁定核苷酸类似物）能够在对互补 RNA 和 DNA 寡聚体的亲和性和特异性方面对寡核苷酸进行有价值的改进。新型 LNA 修饰寡核苷酸以及 LNA 本身可用于广泛的诊断和治疗应用。其中包括反义应用、PCR 应用、链置换寡聚体、核酸聚合底物、核苷酸类药物等。本发明也涉及此类应用。